We are live on ! Find out more
BRM

Boston Research & Management Portfolio holdings

AUM $421M
1-Year Est. Return 16.18%
This Fund
S&P 500
This Quarter Est. Return
-9.76%
1 Year Est. Return
+16.18%
3 Year Est. Return
+48.21%
5 Year Est. Return
+65.09%
10 Year Est. Return
+242.1%
AUM
$210M
AUM Growth
-$8.84M
Cap. Flow
+$15.6M
Cap. Flow %
7.42%
Top 10 Hldgs %
25.12%
Holding
107
New
6
Increased
45
Reduced
11
Closed
7

Sector Composition

Rank Sector Weight
1 Technology 13.92%
2 Healthcare 13.24%
3 Industrials 12.66%
4 Consumer Staples 11.68%
5 Financials 10.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HPQ icon
101
HP
HPQ
$24.9B
-8,880
Closed -$228K
HUBB icon
102
Hubbell
HUBB
$25B
-1,530
Closed -$204K
OXY icon
103
Occidental Petroleum
OXY
$56.8B
-2,980
Closed -$244K
QCOM icon
104
Qualcomm
QCOM
$155B
-2,960
Closed -$213K
TXN icon
105
Texas Instruments
TXN
$252B
-2,060
Closed -$221K
AMJ
106
DELISTED
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
-34,655
Closed -$951K
PX
107
DELISTED
Praxair Inc
PX
-17,770
Closed -$2.86M

Similar funds

Boston Research & Management's Q4 2018 Portfolio in Review

As of Q4 2018, Boston Research & Management held 107 positions worth $210M, down 4% from $219M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Boston Research & Management deployed $15.6M of net new capital in Q4 2018, opening 6 new positions and adding to 45 existing holdings. Its largest new stake was Linde: 14,930 shares worth $2.33M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 15% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was GE Aerospace, an estimated $1.29M trimmed.

  • Boston Research & Management's largest Q4 2018 buy was Linde: 14,930 shares worth $2.33M.
  • Boston Research & Management added most to CVS Health in Q4 2018, an estimated $731K increase.
  • Boston Research & Management's biggest Q4 2018 reduction was GE Aerospace, cutting an estimated $1.29M.
  • Boston Research & Management fully exited Praxair Inc in Q4 2018, selling an estimated $2.86M.
  • Boston Research & Management's ten largest holdings make up 25% of its $210M portfolio in Q4 2018.
  • Boston Research & Management opened 6 new positions and closed 7 in Q4 2018.
  • Boston Research & Management's portfolio value fell 4% quarter-over-quarter to $210M.

Based on Boston Research & Management's 13F filing for Q4 2018, filed 6 Feb 2019.